US2016175282A1PendingUtilityA1

Sphingosine 1 phosphate receptor moduators and their use to treat muscle inflammation

Assignee: LONDEL MARCOPriority: Jul 23, 2008Filed: Feb 26, 2016Published: Jun 23, 2016

Est. expiryJul 23, 2028(~2 yrs left)· nominal 20-yr term from priority

Inventors:Marco Londel Timothy Wright Peter Gergely

A61P 43/00A61P 29/00A61P 21/00A61K 31/397

PatentIndex Score

Cited by

References

Claims

Abstract

SIP receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Claims

exact text as granted — not AI-modified

1 . A method for treating body inclusion myositis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid. 
     
     
         2 . A method for treating dermatomyositis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid.

Join the waitlist — get patent alerts

Track US2016175282A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.